Literature DB >> 7679422

Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif.

G B Lipford1, M Hoffman, H Wagner, K Heeg.   

Abstract

CD8+ cytolytic T cells recognize Ag presented by MHC class I molecules on the surface of target cells. It is known that presenting cells process nascent protein into peptides of approximately eight to nine amino acids which bind to the peptide groove of MHC class I and are transported to the cell surface. Recently, several laboratories have postulated that each MHC class I haplotype has a binding motif of at least two amino acids nested within the peptide. One such motif is XXXXF/YXXL which binds to the mouse MHC class I molecule, H2-Kb, and can be found in the known antigenic peptide from OVA at amino acids 257-264. By using the motif to scan OVA five peptides were found that fit this pattern, OVA 11-18, OVA 55-62, OVA 107-114, OVA 176-183, and OVA 257-264. Binding studies revealed that three out of the five peptides (OVA 55-62, OVA 176-183, and OVA 257-264) bind to MHC class I. To test the natural antigenicity of the predicted peptides, C57BL/6 mice were immunized with OVA containing immunostimulating complexes to elicit a MHC class I-driven response to naturally processed OVA. The cytolytic potential of the responding T cell population was tested in vitro by using EL-4 cells preincubated with the predicted synthetic peptides as targets. The known antigenic peptide OVA 257-264 elicited a strong response; however, OVA 176-183 was also recognized while the remaining three were not recognized. The CTL response did not strictly correlate with the ability of the selected peptides to bind Kb, for example, OVA 55-62 was able to bind Kb efficiently, yet elicited no cytolytic response. In addition, the plasticity of the peptide-binding motif was probed by making amino acid substitutions, and as a result the motif proved to be more flexible than previously suspected. This represents the first report of a Kb-associated CTL epitope within OVA other than OVA 257-264. It also demonstrates the predictive quality of the Kb-binding motif; however, not all predicted peptides were recognized by primary OVA-induced CTL, implying more rules of processing and binding are needed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679422

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Oral administration of antigen does not influence the proliferation and IFN-γ production of responsive CD8+ T cells but enables to establish T cell clones with different lymphokine production profile.

Authors:  K Nishijima; T Hisatsune; H Kato; M Kohyama; M Kakehi; S Hachimura; S Kaminogawa
Journal:  Cytotechnology       Date:  1997-11       Impact factor: 2.058

2.  Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines.

Authors:  R Khanna; S R Burrows; A Neisig; J Neefjes; D J Moss; S L Silins
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway.

Authors:  Dodie S Pouniotis; Vasso Apostolopoulos; Geoffrey A Pietersz
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

4.  Differential effects of flanking residues on presentation of epitopes from chimeric peptides.

Authors:  C C Bergmann; L Tong; R Cua; J Sensintaffar; S Stohlman
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

5.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

Authors:  K J Maloy; A M Donachie; D T O'Hagan; A M Mowat
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

6.  CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells.

Authors:  Caroline A Bernhard; Christine Ried; Stefan Kochanek; Thomas Brocker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-14       Impact factor: 11.205

7.  Design, synthesis and characterisation of mannosylated ovalbumin lipid core peptide self-adjuvanting vaccine delivery system.

Authors:  Pavla Simerska; Zyta Maria Ziora; Vincent Fagan; Daryn Goodwin; Farrah Edrous; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

8.  Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Authors:  Hong Jiang; Yisel Rivera-Molina; Candelaria Gomez-Manzano; Karen Clise-Dwyer; Laura Bover; Luis M Vence; Ying Yuan; Frederick F Lang; Carlo Toniatti; Mohammad B Hossain; Juan Fueyo
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

Review 9.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Characterization of the Ld-restricted cytotoxic T-lymphocyte epitope in the mouse hepatitis virus nucleocapsid protein.

Authors:  C Bergmann; M McMillan; S Stohlman
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.